3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1
    52.
    发明申请
    3,3-DISUBSTITUTED-(8-AZA-BICYCLO[3.2.1]OCT-8-YL)-[5-(1H-PYRAZOL-4-YL)-THIOPHEN-3-YL]-METHANONES AS INHIBITORS OF 11 (BETA)-HSD1 有权
    (8-AZA-BICYCLO [3.2.1] OCT-8-YL) - [5-(1H-吡咯-4-基) - 乙二烯-3-基] - 甲基] BETA)-HSD1

    公开(公告)号:US20130123268A1

    公开(公告)日:2013-05-16

    申请号:US13642963

    申请日:2011-03-10

    摘要: The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, 3,3-disubstituted-(6-aza-bicyclo[3.1.1]hept-6-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone, and 4,4-disubstituted piperidin-1-yl)-[5-(1H-pyrazol-4-yl)-thiophen-3-yl]-methanone compounds of the following formula that, inter alia, inhibit 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.

    摘要翻译: 本发明一般涉及治疗化合物领域。 更具体地,本发明涉及某些3,3-二取代 - (8-氮杂 - 双环[3.2.1]辛-8-基) - [5-(1H-吡唑-4-基) - 噻吩-3-基 ] - 甲酮,3,3-二取代 - (6-氮杂 - 双环[3.1.1]庚-6-基) - [5-(1H-吡唑-4-基) - 噻吩-3-基] - 甲酮, 和4,4-二取代哌啶-1-基) - [5-(1H-吡唑-4-基) - 噻吩-3-基] - 甲酮化合物,特别是抑制11β-羟基类固醇脱氢酶型 1(11beta-HSD1)。 本发明还涉及包含这些化合物的药物组合物,以及这些化合物和组合物在体外和体内都用于抑制1型11β-羟类固醇脱氢酶的用途; 治疗通过抑制1型11β-羟类固醇脱氢酶而改善的病症; 治疗代谢综合征,其包括诸如2型糖尿病和肥胖症的疾病,以及包括胰岛素抵抗,高血压,脂质障碍和心血管疾病如缺血性(冠心病)心脏病的相关疾病; 治疗CNS疾病如轻度认知障碍和早期痴呆,包括阿尔茨海默氏病; 等等

    DIAZACARBAZOLES AND METHODS OF USE
    55.
    发明申请
    DIAZACARBAZOLES AND METHODS OF USE 审中-公开
    DIAZACARBAZOLES和使用方法

    公开(公告)号:US20110124654A1

    公开(公告)日:2011-05-26

    申请号:US12997069

    申请日:2009-06-10

    CPC分类号: C07D471/14

    摘要: The invention relates to 1,5-diazacarbazole compounds of Formula (I), (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g) and (I-h) which are useful as kinase inhibitors, more specifically useful as checkpoint kinase 1 (chk1) inhibitors, thus useful as cancer therapeutics. The invention also relates to compositions, more specifically pharmaceutical compositions comprising these compounds and methods of using the same to treat various forms of cancer and hyperproliferative disorders, as well as methods of using the compounds for in vitro, in situ, and in vivo diagnosis or treatment of mammalian cells, or associated pathological conditions.

    摘要翻译: 本发明涉及有用的式(I),(Ia),(Ib),(Ic),(Id),(Ie),(If),(Ig)和(Ih)的1,5-二氮杂咔唑化合物 作为激酶抑制剂,更具体地用作检查点激酶1(chk1)抑制剂,因此可用作癌症治疗剂。 本发明还涉及包含这些化合物的组合物,更具体地是包含这些化合物的药物组合物以及使用该组合物治疗各种形式的癌症和过度增殖性疾病的方法,以及将该化合物用于体外,原位和体内诊断或 治疗哺乳动物细胞或相关病理状况。